Search Results - mario+mietzsch

3 Results

Sort By:

Recombinant AAV9 Vectors with Modified Capsids for Escaping Neutralizing Human Antibodies

Amino Acid Substitutions on the Capsid Surface to Evade Neutralizing Antibodies and Improve Gene Therapy Efficacy and Safety Adeno-associated virus (AAV)-based vectors are the leading platform for the delivery of gene therapy in vivo, but have a limitation in that they need to avoid neutralizing and potentially dangerous immune response to the AAV...

Published: 9/4/2024 | Inventor(s): Robert McKenna, Mario Mietzsch, Jane Hsi, Austin Nelson

Keywords(s):

Category(s): Technology Classifications > Human Health Care > Gene Therapy, Technology Classifications > Human Health Care > Therapeutics

AAV Vectors for Improved CNS Targeting

Targets Neuronal Cells to Develop Gene Therapies and Treat Neurological Diseases These engineered AAV vectors are designed to target neuronal cell types to aid in the development of gene therapies, which can treat a variety of neurological diseases. In 2020, the market for CNS targeting technologies was worth $6 billion and is expected to reach $46.5...

Published: 7/14/2023 | Inventor(s): Robert McKenna, Mario Mietzsch, Judit Penzes, Mavis Agbandje-McKenna, Chun Yu, Alberto Ybargollin, Alana Johnson, Jane Hsi

Keywords(s):

Category(s): Technology Classifications > Human Health Care > Therapeutics

AAV Gene Therapy Capsid Variants That Evade Neutralizing Antibodies

Enable Patients With Anti-Capsid Antibodies for AAV8 or AAVrh.10 to Participate in Clinical Trials to Undergo Gene Therapy with AAV These adeno-associate vector capsid variants offer antibody-escaping abilities that will enable patients with antibodies against an AAV serotype to receive therapy or participate in clinical trials anyway. Due to the high...

Published: 9/15/2021 | Inventor(s): Mavis Agbandje-McKenna, Mario Mietzsch

Keywords(s):

Category(s): Technology Classifications > Human Health Care > Gene Therapy, Technology Classifications > Human Health Care > Therapeutics